Assetmark Inc. Boosts Holdings in Nevro Corp. (NYSE:NVRO)

Assetmark Inc. increased its stake in shares of Nevro Corp. (NYSE:NVROGet Rating) by 63.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 930 shares of the medical equipment provider’s stock after buying an additional 361 shares during the period. Assetmark Inc.’s holdings in Nevro were worth $43,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in NVRO. Nisa Investment Advisors LLC increased its holdings in Nevro by 27.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,170 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 250 shares during the last quarter. Dupont Capital Management Corp increased its stake in shares of Nevro by 72.4% in the second quarter. Dupont Capital Management Corp now owns 3,354 shares of the medical equipment provider’s stock worth $147,000 after purchasing an additional 1,409 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Nevro in the first quarter worth about $170,000. Strs Ohio increased its stake in shares of Nevro by 6.3% in the second quarter. Strs Ohio now owns 5,100 shares of the medical equipment provider’s stock worth $223,000 after purchasing an additional 300 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Nevro in the first quarter worth about $223,000. Hedge funds and other institutional investors own 96.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NVRO. Wells Fargo & Company reduced their target price on shares of Nevro from $43.00 to $37.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 11th. Citigroup downgraded shares of Nevro from a “buy” rating to a “neutral” rating and set a $40.00 target price for the company. in a research note on Tuesday, January 17th. JPMorgan Chase & Co. reduced their target price on shares of Nevro from $50.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, November 3rd. William Blair reiterated a “market perform” rating on shares of Nevro in a research note on Wednesday, November 2nd. Finally, Canaccord Genuity Group upgraded shares of Nevro from a “hold” rating to a “buy” rating and lifted their target price for the stock from $41.00 to $67.00 in a research note on Tuesday, December 20th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $54.67.

Nevro Trading Up 0.6 %

Shares of Nevro stock opened at $37.92 on Monday. Nevro Corp. has a 1 year low of $34.70 and a 1 year high of $87.71. The firm has a market cap of $1.34 billion, a PE ratio of -114.91 and a beta of 0.86. The company has a debt-to-equity ratio of 0.57, a current ratio of 7.05 and a quick ratio of 5.82. The company has a 50 day simple moving average of $41.06 and a two-hundred day simple moving average of $43.29.

Nevro (NYSE:NVROGet Rating) last announced its earnings results on Wednesday, November 2nd. The medical equipment provider reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. Nevro had a negative net margin of 2.01% and a negative return on equity of 40.89%. The business had revenue of $100.47 million during the quarter, compared to analyst estimates of $99.08 million. Analysts expect that Nevro Corp. will post -2.72 earnings per share for the current fiscal year.

About Nevro

(Get Rating)

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Stories

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp. (NYSE:NVROGet Rating).

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.